Alterity Therapeutics (ATHE) Interest Expenses (2019)

Alterity Therapeutics' (ATHE) quarterly Interest Expenses came in at -$1690.2 in Q4 2019.

Alterity Therapeutics (ATHE) Interest Expenses (2019) Analysis & Trends

Alterity Therapeutics' Interest Expenses history runs 1 years deep, the most recent figure standing at -$1690.2 for Q4 2019.

On a quarterly basis, Interest Expenses changed N/A year-over-year to -$1690.2 in Q4 2019; TTM through Jun 2021 was -$1690.2, a 0.0% change from a year earlier, with the FY2025 full-year figure at $3963.0, down 16.68% from the prior year.
Interest Expenses held at -$1690.2 in Q4 2019 per ATHE's latest filing.
Across five years, Interest Expenses topped out at -$1690.2 in Q4 2019 and bottomed at -$1690.2 in Q4 2019.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Int Expense (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-42,141.15
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	100,000.00
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	32.89 Mn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	420.30 Mn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	28.30 Mn
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	1.17 Bn
10	Alterity Therapeutics	29.68 Bn	29.68 Bn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2019	-1,690.21
Dec 31, 2019	-1,690.21